Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz.
Covino DA, Purificato C, Catapano L, Galluzzo CM, Gauzzi MC, Vella S, Lefebvre E, Seyedkazemi S, Andreotti M, Fantuzzi L. Covino DA, et al. Among authors: galluzzo cm. Front Immunol. 2018 Aug 8;9:1839. doi: 10.3389/fimmu.2018.01839. eCollection 2018. Front Immunol. 2018. PMID: 30135687 Free PMC article.
Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing.
Sarmati L, Nicastri E, Uccella I, D'Ettorre G, Parisi SG, Palmisano L, Galluzzo C, Concia E, Vullo V, Vella S, Andreoni M. Sarmati L, et al. J Clin Microbiol. 2003 Apr;41(4):1760-2. doi: 10.1128/JCM.41.4.1760-1762.2003. J Clin Microbiol. 2003. PMID: 12682180 Free PMC article.
High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis.
Nicastri E, Sarmati L, d'Ettorre G, Parisi SG, Palmisano L, Galluzzo C, Montano M, Uccella I, Amici R, Gatti F, Vullo V, Concia E, Vella S, Andreoni M. Nicastri E, et al. J Clin Microbiol. 2003 Jul;41(7):3007-12. doi: 10.1128/JCM.41.7.3007-3012.2003. J Clin Microbiol. 2003. PMID: 12843034 Free PMC article. Clinical Trial.
Development of a human immunodeficiency virus vector-based, single-cycle assay for evaluation of anti-integrase compounds.
Bona R, Andreotti M, Buffa V, Leone P, Galluzzo CM, Amici R, Palmisano L, Mancini MG, Michelini Z, Di Santo R, Costi R, Roux A, Pommier Y, Marchand C, Vella S, Cara A. Bona R, et al. Among authors: galluzzo cm. Antimicrob Agents Chemother. 2006 Oct;50(10):3407-17. doi: 10.1128/AAC.00517-06. Antimicrob Agents Chemother. 2006. PMID: 17005823 Free PMC article.
Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: the Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) study.
Palmisano L, Giuliano M, Bucciardini R, Fragola V, Andreotti M, Galluzzo C, Pirillo MF, Weimer LE, Arcieri R, Germinario EA, Amici R, Mancini MG, Monforte Ad, Castelli F, Caramello P, Vella S; Italian ISS-PART Clinical Centers. Palmisano L, et al. J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):39-47. J Acquir Immune Defic Syndr. 2007. PMID: 17972364 Clinical Trial.
99 results